MX2013003168A - Anticuerpo contra ephrin b2 y su uso. - Google Patents

Anticuerpo contra ephrin b2 y su uso.

Info

Publication number
MX2013003168A
MX2013003168A MX2013003168A MX2013003168A MX2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A
Authority
MX
Mexico
Prior art keywords
ephrin
antibody
lymphangiogenesis
cancer
drug
Prior art date
Application number
MX2013003168A
Other languages
English (en)
Inventor
Torrecuadrada Jorge Luis Martinez
Infantes Maria Angeles Abengozar
Original Assignee
Fundacion Ct Nac De Investigaciones Oncologicas Cnio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Ct Nac De Investigaciones Oncologicas Cnio filed Critical Fundacion Ct Nac De Investigaciones Oncologicas Cnio
Publication of MX2013003168A publication Critical patent/MX2013003168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un nuevo anticuerpo contra ephrin B2 y a su uso para detectar dicha proteína y como medicamento para inhibir la angiogénesis y la linfoangiogénesis, en el tratamiento de enfermedades en las que estos procesos están implicados como, por ejemplo, el cáncer.
MX2013003168A 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso. MX2013003168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso

Publications (1)

Publication Number Publication Date
MX2013003168A true MX2013003168A (es) 2013-08-21

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003168A MX2013003168A (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso.

Country Status (12)

Country Link
US (1) US9062109B2 (es)
EP (1) EP2620449A4 (es)
JP (1) JP2013542720A (es)
KR (1) KR20140014062A (es)
CN (1) CN103237812A (es)
AU (1) AU2011306816A1 (es)
BR (1) BR112013005977A2 (es)
CA (1) CA2812727A1 (es)
ES (1) ES2378976B1 (es)
MX (1) MX2013003168A (es)
RU (1) RU2013118454A (es)
WO (1) WO2012038573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
US20220064285A1 (en) * 2018-12-28 2022-03-03 The General Hospital Corporation Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases
EP3969478A1 (en) * 2019-05-14 2022-03-23 Sanford Health Anti-human ephrin b1 antibodies and uses thereof
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer
TW202547871A (zh) * 2024-03-27 2025-12-16 美商麥第爾醫療公司 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
CA2627890A1 (en) * 2005-10-31 2007-05-10 The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
KR101459160B1 (ko) * 2006-01-20 2014-11-19 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
ATE514714T1 (de) * 2007-03-19 2011-07-15 Univ Stuttgart Hutnfr1-selektive antagonisten
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Also Published As

Publication number Publication date
BR112013005977A2 (pt) 2019-09-24
EP2620449A1 (en) 2013-07-31
US20130287795A1 (en) 2013-10-31
KR20140014062A (ko) 2014-02-05
WO2012038573A1 (es) 2012-03-29
CA2812727A1 (en) 2012-03-29
JP2013542720A (ja) 2013-11-28
ES2378976A1 (es) 2012-04-19
CN103237812A (zh) 2013-08-07
AU2011306816A1 (en) 2013-04-04
ES2378976B1 (es) 2013-05-06
RU2013118454A (ru) 2014-10-27
EP2620449A4 (en) 2014-03-26
US9062109B2 (en) 2015-06-23

Similar Documents

Publication Publication Date Title
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
NZ630542A (en) Methods of treating a tauopathy
PH12014501039B1 (en) Cytotoxic peptides and antibody drug conjugates thereof
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TN2015000396A1 (en) Antibody drug conjugates
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
GB201118656D0 (en) New compounds
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX349004B (es) Nuevos compuestos.
SG10201903119QA (en) Polypeptide vaccine
GB201209613D0 (en) New compounds
TN2012000414A1 (en) Forms of rifaximin and uses thereof
IL235672A0 (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
WO2013114367A8 (en) C10rf32 antibodies, and uses thereof for treatment of cancer
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX366899B (es) Nuevos compuestos.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
SMT201700387T1 (it) Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
WO2013053034A3 (pt) Tiazacridinas utilizadas na terapia anticâncer
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal